Nicotinamide for the treatment of heart failure with preserved ejection fraction

Q: What is the clinical evidence from this study?

Study design: Cohort. Population: General population. Intervention: Dietary intake of NAD+ precursors (niacin equivalents) vs. Lower dietary intake. Primary outcome: All-cause death and cardiac mortality.

Mahmoud Abdellatif; Viktoria Trummer-Herbst; Franziska Koser; Sylvère Durand; Rui Adão; Francisco Vasques‐Nóvoa; Johanna K. Freundt; Julia Voglhuber; María Rosaria Pricolo; Michael Kasa; Clara Türk; Fanny Aprahamian; Elías Herrero‐Galán; Sebastian J. Hofer; Tobias Pendl; Lavinia Rech; Julia Kargl; Nathaly Anto-Michel; Senka Ljubojević-Holzer; Julia Schipke; Christina Brandenberger; Martina Auer; Renate Schreiber; Chintan N. Koyani; Ákos Heinemann; Andreas Zirlik; Albrecht Schmidt; Dirk von Lewinski; Peter P. Rainer; Julia von Maltzahn; Christian Mühlfeld; Marcus Krüger; Saša Frank; Frank Madeo; Tobias Eisenberg; Andreas Prokesch; Adelino Leite‐Moreira; André P. Lourenço; Jorge Alegre‐Cebollada; Stefan Kiechl; Wolfgang A. Linke; Guido Kroemer; Simon Sedej

doi:10.1126/scitranslmed.abd7064

February 10, 2021Science Translational MedicineOpen Access

Nicotinamide for the treatment of heart failure with preserved ejection fraction

View Full Paper

Ask AI

Bookmark

Share

Why the study?

Does nicotinamide improve outcomes in humans with diastolic dysfunction and HFpEF?

Study Design

Type

Cohort

Structured PICO

Does nicotinamide improve outcomes in humans with diastolic dysfunction and HFpEF?

P

Population

Participants from the prospective population-based Bruneck cohort followed for 20 years to evaluate the association between dietary NAD+ precursor intake and mortality.

E

Exposure

Nicotinamide

Limitations

Potential residual confounding influence by other nutritional ingredients or dietary patterns linked to NAD+ precursor intake
Use of surrogate endpoints rather than HFpEF itself in the epidemiological cohort
Data on signs and symptoms were not always available at the time of death/donation for the human LV biopsy samples

Implication

Nicotinamide is highlighted as a potential therapeutic agent for treating diastolic dysfunction and HFpEF.

Abstract

precursors, and especially nicotinamide, as potential therapeutic agents to treat diastolic dysfunction and HFpEF in humans.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Abdellatif et al. (2021) conducted a cohort in General population. Dietary intake of NAD+ precursors (niacin equivalents) vs. Lower dietary intake was evaluated on All-cause death and cardiac mortality.

synapsesocial.com/papers/6a7c97040bb6134e42cf7ec1 https://doi.org/10.1126/scitranslmed.abd7064

Topics

HFrEF treatment

Heart failure

HFpEF management

View Full Paper

Ask AI

Bookmark

Share

Nicotinamide for the treatment of heart failure with preserved ejection fraction

Study Design

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Topics

Nicotinamide for the treatment of heart failure with preserved ejection fraction

Study Design

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More on HFrEF treatment

More from Science Translational Medicine

Topics

Keep reading

More related papers

More on HFrEF treatment

More from Science Translational Medicine